Biosimilars for IBD: Making the Transition Webinar

Written by: CDHF
Updated: May 28th, 2026
Dr. McCurdy answered the following questions in a very informative webinar presentation on Biosimilars:
- What’s the difference between a reference biologic drug and a biosimilar?
- Biosimilars: What’s Health Canada saying?
- What is the clinical evidence to date?
- How do doctors go about transitioning their patients from a reference biologic drug to a biosimilar?
Read more on biosimilars by visiting our Biosimilar Library here.
Related Articles:
View all News & Articles
Infliximab for the Treatment of Inflammatory Bowel Disease: An Overview of Drug History and Delivery



























































































